reviewed april 2026|next review october 2026|88 physicians psi has verified|42793 published studies
Gonadorelin
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH) approved by the FDA as Factrel for diagnostic testing of pituitary gonadotroph function. It is used in clinical practice for both diagnostic and therapeutic applications, including fertility preservation during testosterone replacement therapy.
Evidence landscape: 42793 published studies
42,793 published items (inflated by broad GnRH query). 37 human studies and 138 animal studies indexed for this slug. The GnRH axis is one of the most studied in endocrinology.
- 37 Human
- 138 Animal
- 25 Reviews
- 42593 Other research
FDA-approved as Factrel for diagnostic pituitary function testing. Available through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient, for therapeutic off-label use.
Increasingly used in functional medicine for fertility preservation during testosterone replacement therapy (TRT). This application is supported by clinical practice and mechanistic rationale but not by large controlled trials.
Pulsatile administration maintains receptor sensitivity and stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production. Continuous administration causes receptor downregulation and paradoxical suppression. This distinction separates gonadorelin from GnRH agonists like leuprolide (Lupron).
PSI Assessment
The entire reproductive hormone cascade starts with a single signal: gonadotropin-releasing hormone, pulsed from the hypothalamus every 60 to 90 minutes. Gonadorelin is a synthetic version of that signal. It is FDA-approved as Factrel for diagnostic testing of pituitary function, and it is increasingly used in functional medicine to preserve fertility and testicular function during testosterone replacement therapy, an application supported by clinical practice but not by large controlled trials.
FDA-approved for pituitary diagnostics. Increasingly used for fertility preservation during testosterone therapy. The controlled trial evidence for the second use is thin.
The mechanism is GnRH receptor activation on pituitary gonadotroph cells, stimulating release of LH and FSH, the hormones that drive testosterone production and spermatogenesis. The critical pharmacological distinction: pulsatile administration maintains receptor sensitivity and hormone production. Continuous administration (as with GnRH agonists like leuprolide) causes receptor downregulation and paradoxical suppression. That difference between pulsatile and continuous is what separates gonadorelin from drugs like Lupron.
What the evidence supports
FDA-approved for diagnostic pituitary function testing. The GnRH mechanism is the most characterized endocrine signaling pathway. Pulsatile administration maintains LH/FSH production and fertility.
What is not yet established
Controlled trial evidence for fertility preservation during testosterone replacement therapy. Whether gonadorelin is superior to HCG for this application. Long-term outcomes of pulsatile GnRH therapy in the TRT setting.
Research Evidence
The findings below cover the established diagnostic use, the fertility preservation rationale, and the open questions for the TRT-adjacent application.
Evidence by condition
Evidence dimensions across gonadorelin's approved and investigated uses. Diagnostic pituitary testing has the deepest evidence. Fertility preservation during TRT has mechanism support but limited controlled human data.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Pituitary Function Testing | ||||
| Fertility Preservation during TRT | ||||
| Hypogonadotropic Hypogonadism |
The single-injection GnRH stimulation test is a validated diagnostic tool for distinguishing hypothalamic from pituitary causes of hypogonadism. LH and FSH responses are measured at timed intervals. This is the basis for the FDA-approved indication.
Diagnostic pituitary testing has decades of clinical use and is standard of care in endocrinology.
Pulsatile GnRH replacement restores LH/FSH secretion and fertility in patients with hypothalamic hypogonadism. The Crowley landmark study demonstrated that mimicking the natural GnRH pulse pattern maintains the reproductive axis.
This is the mechanistic foundation for using gonadorelin during TRT: if pulsatile GnRH maintains the axis in hypogonadotropic patients, it should maintain the axis when exogenous testosterone suppresses the body's own GnRH production.
Clinical reviews summarize the rationale for gonadorelin and human chorionic gonadotropin (HCG) use during TRT for fertility preservation. The evidence base is clinical practice and case series rather than randomized controlled trials.
The gap between widespread clinical use and controlled trial evidence is the defining feature of gonadorelin's therapeutic profile outside the diagnostic indication.
37 Human|138 Animal|25 Reviews
View all 42793 indexed studiesHow Gonadorelin Works
Gonadorelin is a synthetic decapeptide identical to the body's own gonadotropin-releasing hormone (GnRH). It activates GnRH receptors on pituitary gonadotroph cells.
Your brain produces GnRH in pulses to tell your pituitary gland to release the hormones (LH and FSH) that drive testosterone production and sperm production. When you take TRT, your brain stops making GnRH because it detects enough testosterone. Gonadorelin mimics that natural GnRH pulse, keeping the signal alive so your testes keep working.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Gonadorelin (pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) is identical to the body's native GnRH. It binds the GnRH receptor (GnRHR), a Gq-coupled receptor on anterior pituitary gonadotrophs. Pulsatile binding activates phospholipase C, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which trigger LH and FSH synthesis and secretion. Continuous receptor occupancy (as with long-acting GnRH agonists) causes receptor internalization and downregulation, paradoxically suppressing gonadotropin release. This pharmacological distinction is the basis for using pulsatile gonadorelin to maintain fertility while using continuous GnRH agonists to suppress reproductive hormones.
What is Gonadorelin being studied for?
Researchers are studying Gonadorelin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Gonadorelin overall. This means a compound can have human studies for one condition but only animal data for another.
Pituitary Function Testing
·FDA ApprovedFDA-approved as Factrel for evaluating pituitary gonadotroph function. Administered as a single injection with LH measured at timed intervals.
Limitations: Diagnostic use only. Does not treat the underlying condition.
Fertility Preservation during TRT
·Animal StudiesWidely used in functional medicine to maintain testicular function and spermatogenesis during testosterone replacement therapy. Clinical evidence is limited to observational data and small studies.
Limitations: No large randomized controlled trials. Most evidence is from clinical practice rather than published studies.
Hypogonadotropic Hypogonadism
·Human TrialsPulsatile GnRH therapy can restore fertility in men with hypothalamic hypogonadism by mimicking the natural GnRH pulse pattern.
Limitations: Requires pulsatile delivery via pump. Subcutaneous injection protocols used in functional medicine differ from the pump approach.
Safety and Regulatory Status
FDA Status: FDA-approved as Factrel for diagnostic pituitary function testing. Not FDA-evaluated for therapeutic fertility preservation during TRT.
Availability: Available by prescription. Therapeutic use is through specialty pharmacies, where a licensed pharmacist prepares a medicine from ingredients for an individual patient.
Injection-site reactions are the most common side effect. Headache, nausea, and flushing are occasionally reported. Allergic reactions are rare.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Gonadorelin discussion.
Comparison and Related Research
Gonadorelin is most often compared with other agents used to maintain reproductive function during testosterone therapy.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Foundational review of GnRH pharmacology. Established the distinction between pulsatile stimulation (maintains fertility) and continuous exposure (causes suppression). Defined the pharmacological framework for all subsequent GnRH therapies.Conn PM et al., 1982 in Endocr Rev. View on PubMed
- 2.Landmark study characterizing pulsatile GnRH secretion patterns and demonstrating that pulsatile GnRH replacement restores fertility in hypogonadotropic patients.Crowley WF et al., 1985 in N Engl J Med. View on PubMed
- 3.Clinical validation of the single-injection gonadorelin stimulation test. Established the diagnostic cutoffs for LH and FSH responses that distinguish pituitary dysfunction from hypothalamic causes.Roth MY et al., 2005 in J Clin Endocrinol Metab. View on PubMed
- 4.Review of gonadorelin and HCG for fertility preservation during TRT. Summarizes the clinical rationale and available evidence for maintaining spermatogenesis while on exogenous testosterone.Lee JA et al., 2021 in Transl Androl Urol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.